Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 22,004	$ 84,978
Property, plant and improvements, net	1,445,816	1,445,415
Other receivables	465,120	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	775,328	775,328
Deferred lease expense	190,058	217,210
Intangible assets, net	6,018,177	6,230,583
Total assets	8,961,362	9,020,935
Current liabilities
Accounts payable	171,805	104,828
Loans payable	10,117,369	9,981,883
Loans payable – related parties	1,062,090	838,923
Convertible notes payable	2,388,806	1,461,979
Convertible notes payable – related parties	1,098,000	2,210,313
Accrued interest	5,684,981	4,540,692
Accrued interest – related parties	768,997	592,901
Accrued expenses	339,977	295,874
Total current liabilities	21,632,025	20,027,393
Patent acquisition liability	620,000	5,000,000
Loans payable – related parties, less current portion	300,000	300,000
Convertible notes payable, less current portion	1,927,518	2,208,193
Convertible notes payable – related parties, less current portion	1,612,313	500,000
Total liabilities	26,091,856	28,035,586
Commitments and contingencies
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,373,243 and 25,131,843 issued and outstanding as of June 30, 2018 and December 31, 2017, respectively. No par value.
Additional paid-in capital	13,974,509	9,110,041
Accumulated deficit	(31,105,003)	(28,124,692)
Total shareholders’ deficit	(17,130,494)	(19,014,651)
Total liabilities and shareholders’ deficit	$ 8,961,362	$ 9,020,935